226 related articles for article (PubMed ID: 12786807)
1. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
Fischer R; Longo F; Nielsen P; Engelhardt R; Hider RC; Piga A
Br J Haematol; 2003 Jun; 121(6):938-48. PubMed ID: 12786807
[TBL] [Abstract][Full Text] [Related]
2. Oral deferiprone for iron chelation in people with thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
4. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
6. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
Aydinok Y; Evans P; Manz CY; Porter JB
Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
[TBL] [Abstract][Full Text] [Related]
7. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
8. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
Mourad FH; Hoffbrand AV; Sheikh-Taha M; Koussa S; Khoriaty AI; Taher A
Br J Haematol; 2003 Apr; 121(1):187-9. PubMed ID: 12670352
[TBL] [Abstract][Full Text] [Related]
9. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Kontoghiorghes GJ; Kolnagou A
Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
[No Abstract] [Full Text] [Related]
10. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
13. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
Aydinok Y; Nisli G; Kavakli K
Br J Haematol; 1999 Jul; 106(1):252-3. PubMed ID: 10444196
[No Abstract] [Full Text] [Related]
14. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
Loebstein R; Dalal I; Nisbet-Brown E; Berkovitch M; Meydan N; Andrews D; Loubser MD; Koren G; Roifman CM; Olivieri NF
Br J Haematol; 1997 Sep; 98(3):597-600. PubMed ID: 9332313
[TBL] [Abstract][Full Text] [Related]
15. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone.
Nielsen P; Fischer R; Engelhardt R; Tondüry P; Gabbe EE; Janka GE
Br J Haematol; 1995 Dec; 91(4):827-33. PubMed ID: 8547125
[TBL] [Abstract][Full Text] [Related]
16. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
Waheed N; Ali S; Butt MA
J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
[TBL] [Abstract][Full Text] [Related]
17. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
Christoforidis A; Haritandi A; Tsatra I; Tsitourides I; Karyda S; Athanassiou-Metaxa M
Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
[TBL] [Abstract][Full Text] [Related]
18. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
al-Refaie FN; Wickens DG; Wonke B; Kontoghiorghes GJ; Hoffbrand AV
Br J Haematol; 1992 Oct; 82(2):431-6. PubMed ID: 1419825
[TBL] [Abstract][Full Text] [Related]
19. Combined oral and parenteral iron chelation in beta thalassaemia major.
Balveer K; Pyar K; Wonke B
Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
[TBL] [Abstract][Full Text] [Related]
20. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey.
Aydinok Y; Nisli G; Kavakli K; Coker C; Kantar M; Cetingül N
Acta Haematol; 1999; 102(1):17-21. PubMed ID: 10473883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
